The latest update is out from Jazz Pharmaceuticals (JAZZ).
Jazz Pharmaceuticals has welcomed Patrick Kennedy as a new Class I director, with his term beginning March 1, 2024, and running until the annual shareholder meeting later that year. He will also join the Audit Committee. His appointment came without prior arrangements with others and will be compensated in line with the company’s existing policies for non-employee directors. Furthermore, Peter Gray has announced he will not seek re-election once his term ends at the 2024 Annual Meeting, with no disputes influencing his departure.
For detailed information about JAZZ stock, go to TipRanks’ Stock Analysis page.
